98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.amjcard.2009.09.024 | DOI Listing |
Eur J Oral Sci
September 2025
State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Research Unit of Oral Carcinogenesis and Management, Chinese Academy of Medical Sciences, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, People's Re
Oral lichen planus (OLP) is a chronic inflammatory disease of unknown aetiology, which is an oral potentially malignant disorder. Many investigators suggest that OLP may be a localized autoimmune response caused by cell-mediated autoimmunity to basal cells. However, it remains unclear whether allergens play a role in the pathogenesis of OLP.
View Article and Find Full Text PDFSemin Dial
September 2025
Department of Nephrology, Atal Bihari Vajpayee Institute of Medical Sciences and Dr. Ram Manohar Lohia Hospital, New Delhi, India.
Background: In hyponatremic patients, concurrent dialysate flow during hemodialysis may be an ideal option to mitigate complications such as osmotic demyelination syndrome (ODS).
Methods: Present randomized controlled trial enrolled dialysis-requiring chronic kidney disease (CKD) and acute kidney injury (AKI) patients with serum sodium levels < 125 mEq/L during January 2020 over 16 months. Hemodynamically unstable patients, as well as those with a history of seizures and neurological conditions, were excluded.
Obesity (Silver Spring)
September 2025
Eli Lilly and Company, Indianapolis, Indiana, USA.
Objective: SURMOUNT-MAINTAIN aims to evaluate the efficacy and safety of reducing the tirzepatide dose and/or continuing the maximum tolerated dose (MTD) versus placebo in maintaining body weight (BW) reduction achieved with tirzepatide MTD.
Methods: This Phase 3b, multicenter, randomized, parallel-arm, double-blinded, placebo-controlled, 52-week clinical trial is in progress comparing treatment with once weekly tirzepatide (5 mg and/or MTD of 15 mg or 10 mg) versus placebo in achieving BW reduction maintenance from the initial 60-week open-label weight-loss period on tirzepatide MTD, in adults with obesity (BMI ≥ 30 kg/m or ≥ 27 kg/m with ≥ 1 obesity-related comorbidity, excluding type 2 diabetes). The primary endpoint is percent maintenance of BW reduction achieved during the weight-loss period at Week 112 among those who reached a BW plateau (i.
J Dent Educ
September 2025
College of Dentistry, The Ohio State University, Columbus, Ohio, USA.
Emerg Radiol
September 2025
Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Pancreaticoduodenectomy, also known as the classic Whipple procedure, is the most common surgical treatment for pancreatic adenocarcinoma. Postoperative complications are common and occur in approximately 50% of patients. Prompt detection and management of these complications is vital for improving patient outcomes.
View Article and Find Full Text PDF